Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Siguret

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Thrombosis and Haemostasis|September 1, 1996
Characterization of recombinant von Willebrand factors mutated on cysteine 509 or 695V Siguret, A S Ribba, O Christophe, et al.
Annales De Biologie Clinique|October 19, 2005
[Plasma cell leukaemia]C Rodriguez, J-C Pont, I Gouin-Thibault, et al.
Journal of Clinical Pharmacy and Therapeutics|April 11, 2012
Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patientsF Z Smires, C Moreau, R Habbal, et al.
Thrombosis and Haemostasis|October 18, 1993
Functional analysis of the Arg91Gln substitution in the factor VIII binding domain of von Willebrand factor demonstrates variable phenotypic expressionJ M Lavergne, Y Piao, A S Ribba, et al.
European Review for Medical and Pharmacological Sciences|September 23, 2020
Imbalance between procoagulant factors and natural coagulation inhibitors contributes to hypercoagulability in the critically ill COVID-19 patient: clinical implicationsS Voicu, M Delrue, B G Chousterman, et al.
Journal of Thrombosis and Haemostasis : JTH|November 29, 2016
Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycinI Gouin-Thibault, X Delavenne, A Blanchard, et al.
Annales Pharmaceutiques Francaises|July 7, 2014
[Evaluation of the impact of a training program on vitamin K antagonists (VKA) implemented by pharmacy students aiming at improving the knowledge of patients receiving vitamin K antagonists during their hospital clinical training course]O Conort, V Siguret, O Bourdon, et al.
La Revue De Medecine Interne|March 26, 2013
[Anticoagulant clinics are they effective in France? Performance evaluation of six anticoagulant clinics concerning the management of vitamin K antagonists]J P Cambus, D Magnin, C Ambid-Lacombe, et al.
Clinical Pharmacology and Therapeutics|October 2, 2009
Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatientsE Pautas, C Moreau, I Gouin-Thibault, et al.
The British Journal of Dermatology|October 6, 2021
Type I interferon response and vascular alteration in chilblain-like lesions during the COVID-19 outbreakL Frumholtz, J-D Bouaziz, M Battistella, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Thrombosis and Haemostasis|September 1, 1996
Characterization of recombinant von Willebrand factors mutated on cysteine 509 or 695V Siguret, A S Ribba, O Christophe, et al.
Annales De Biologie Clinique|October 19, 2005
[Plasma cell leukaemia]C Rodriguez, J-C Pont, I Gouin-Thibault, et al.
Journal of Clinical Pharmacy and Therapeutics|April 11, 2012
Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patientsF Z Smires, C Moreau, R Habbal, et al.
Thrombosis and Haemostasis|October 18, 1993
Functional analysis of the Arg91Gln substitution in the factor VIII binding domain of von Willebrand factor demonstrates variable phenotypic expressionJ M Lavergne, Y Piao, A S Ribba, et al.
European Review for Medical and Pharmacological Sciences|September 23, 2020
Imbalance between procoagulant factors and natural coagulation inhibitors contributes to hypercoagulability in the critically ill COVID-19 patient: clinical implicationsS Voicu, M Delrue, B G Chousterman, et al.
Journal of Thrombosis and Haemostasis : JTH|November 29, 2016
Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycinI Gouin-Thibault, X Delavenne, A Blanchard, et al.
Annales Pharmaceutiques Francaises|July 7, 2014
[Evaluation of the impact of a training program on vitamin K antagonists (VKA) implemented by pharmacy students aiming at improving the knowledge of patients receiving vitamin K antagonists during their hospital clinical training course]O Conort, V Siguret, O Bourdon, et al.
La Revue De Medecine Interne|March 26, 2013
[Anticoagulant clinics are they effective in France? Performance evaluation of six anticoagulant clinics concerning the management of vitamin K antagonists]J P Cambus, D Magnin, C Ambid-Lacombe, et al.
Clinical Pharmacology and Therapeutics|October 2, 2009
Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatientsE Pautas, C Moreau, I Gouin-Thibault, et al.
The British Journal of Dermatology|October 6, 2021
Type I interferon response and vascular alteration in chilblain-like lesions during the COVID-19 outbreakL Frumholtz, J-D Bouaziz, M Battistella, et al.
Pageof 5